Critical questions need addressing before any clinical use of in vitro gametogenesis (IVG), says a new report by a Lancaster ...

Our fair value estimate is $20.50 per share. Our long-term sales assumption relies on continued innovation from the firm—which allocates 4% of sales to research and development—as well as long-term ...